Responses
Clinical/translational cancer immunotherapy
Original research
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
Compose a Response to This Article
Other responses
No responses have been published for this article.